Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Fresenius Medical Care AG & Co. KGaA FMS

Healthcare - Medical - Care Facilities - NYSE - DE

Watchlist

$ 22.18

4.03 %

$ 13 B

Market Cap

18.64

P/E

1. INTRINSIC VALUE

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products.[ Read More ]

The intrinsic value of one FMS stock under the base case scenario is HIDDEN Compared to the current market price of 22.2 USD, Fresenius Medical Care AG & Co. KGaA is HIDDEN

FMS Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart FMS

FINANCIALS

Annual
Quarterly

19.5 B REVENUE

Growth Rates

1Year 0.29%

3Years 2.89%

5Years 3.29%

7Years 1.92%

10Years 6.28%

1.37 B OPERATING INCOME

Growth Rates

1Year 630.04%

3Years 37.31%

5Years -14.73%

7Years -8.28%

10Years -1.75%

732 M NET INCOME

Growth Rates

1Year -18.16%

3Years -20.08%

5Years -19.93%

7Years -9.50%

10Years -2.14%

2.63 B OPERATING CASH FLOW

Growth Rates

1Year 21.31%

3Years -14.68%

5Years 4.98%

7Years 3.73%

10Years 5.96%

-544 M INVESTING CASH FLOW

Growth Rates

1Year 25.93%

3Years 25.85%

5Years -17.30%

7Years 11.81%

10Years 4.62%

-1.86 B FINANCING CASH FLOW

Growth Rates

1Year -14.91%

3Years 11.31%

5Years -22.21%

7Years -18.81%

10Years -12.25%

4.76 B REVENUE

Growth Rates

1Year 0.29%

3Years 2.89%

5Years 3.29%

7Years 1.92%

10Years 6.28%

463 M OPERATING INCOME

Growth Rates

1Year 630.04%

3Years 37.31%

5Years -14.73%

7Years -8.28%

10Years -1.75%

265 M NET INCOME

Growth Rates

1Year -18.16%

3Years -20.08%

5Years -19.93%

7Years -9.50%

10Years -2.14%

984 M OPERATING CASH FLOW

Growth Rates

1Year 21.31%

3Years -14.68%

5Years 4.98%

7Years 3.73%

10Years 5.96%

600 M INVESTING CASH FLOW

Growth Rates

1Year 25.93%

3Years 25.85%

5Years -17.30%

7Years 11.81%

10Years 4.62%

0 FINANCING CASH FLOW

Growth Rates

1Year -14.91%

3Years 11.31%

5Years -22.21%

7Years -18.81%

10Years -12.25%

Balance Sheet Decomposition Fresenius Medical Care AG & Co. KGaA

33.9 B ASSETS
19.1 B LIABILITIES

Current Assets	8.7 B
Cash & Short-Term Investments	1.56 B
Receivables	4.06 B
Other Current Assets	3.08 B
Non-Current Assets	25.2 B
Long-Term Investments	1.08 B
PP&E	7.45 B
Other Non-Current Assets	16.7 B

Current Liabilities	6.11 B
Accounts Payable	839 M
Short-Term Debt	1.59 B
Other Current Liabilities	3.68 B
Non-Current Liabilities	13 B
Long-Term Debt	10.5 B
Other Non-Current Liabilities	2.5 B

EFFICIENCY

Earnings Waterfall Fresenius Medical Care AG & Co. KGaA

Revenue	19.5 B
Cost Of Revenue	14.5 B
Gross Profit	4.92 B
Operating Expenses	3.56 B
Operating Income	1.37 B
Other Expenses	637 M
Net Income	732 M

RATIOS

25.31% GROSS MARGIN

Averages

1Year 25.31%

3Years 27.17%

5Years 28.68%

7Years 29.76%

10Years 30.40%

7.04% OPERATING MARGIN

Averages

1Year 7.04%

3Years 2.47%

5Years 2.89%

7Years 6.58%

10Years 8.90%

2.57% NET MARGIN

Averages

1Year 2.57%

3Years 3.85%

5Years 4.98%

7Years 6.30%

10Years 6.38%

3.66% ROE

Averages

1Year 3.66%

3Years 4.99%

5Years 6.69%

7Years 8.66%

10Years 9.17%

1.47% ROA

Averages

1Year 1.47%

3Years 2.06%

5Years 2.70%

7Years 3.77%

10Years 3.91%

4.51% ROIC

Averages

1Year 4.51%

3Years 1.58%

5Years 1.83%

7Years 4.46%

10Years 5.65%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Fresenius Medical Care AG & Co. KGaA

Net Income	732 M
Depreciation & Amortization	1.75 B
Capital Expenditures	-685 M
Stock-Based Compensation	32.5 M
Change in Working Capital	561 M
Others	291 M
Free Cash Flow	1.94 B

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Fresenius Medical Care AG & Co. KGaA

Wall Street analysts predict an average 1-year price target for FMS of $21.7 , with forecasts ranging from a low of $11.7 to a high of $27 .

FMS Lowest Price Target Wall Street Target

11.7 USD -47.25%

FMS Average Price Target Wall Street Target

21.7 USD -2.28%

FMS Highest Price Target Wall Street Target

27 USD 21.73%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0.688 USD DIVIDEND PER SHARE

5. COMPETITION

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments.

177 USD

UHS

Overvalued 12.10%

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States.

127 USD

ADUS

Undervalued 6.13%

HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

146 USD

HCA

Overvalued 57.28%

Tenet Healthcare Corporation operates as a diversified healthcare services company. The company operates in three segments: Hospital Operations and Other, Ambulatory Care, and Conifer.

23.9 USD

THC

Overvalued 84.58%

Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States.

78.8 USD

SEM

Undervalued 110.50%

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice.

26.5 USD

EHC

Overvalued 73.20%

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services.

-4.62 USD

PNTG

Overvalued 114.71%

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities.

-2.95 USD

INNV

Overvalued 156.09%

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company offers behavioral healthcare services to its patients in various settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics.

25.5 USD

ACHC

Overvalued 32.64%

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company operates in two segments, Skilled Services and Real Estate.

141 USD

ENSG

Overvalued 1.40%

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States.

1.51 USD

SGRY

Overvalued 93.40%

6. Ownership

Insider Ownership Fresenius Medical Care AG & Co. KGaA

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price

7. News

Why Fresenius (FMS) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 2 days ago

Is Fresenius Medical Care AG & Co. (FMS) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 5 days ago

Fresenius Medical Q3 Earnings Beat Estimates, Operating Margin Rises FMS' third-quarter results showcase a strong segmental performance. The company raises its full-year 2024 outlook for operating income. zacks.com - 1 week ago

Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 1 week ago

Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings. youtube.com - 1 week ago

Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript Fresenius Medical Care AG (NYSE:FMS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg Robert Davies - Morgan Stanley Hugo Solvet - BNP Paribas Oliver Metzger - ODDO BHF Bank Sezgi Oezener - HSBC Giang Nguyen - Citigroup David Adlington - JPMorgan Marianne Bulot - Bank of America Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator Ladies and gentlemen, welcome to the report of the Third Quarter 2024 of Fresenius Medical Care Conference Call. I'm Sandra, the Chorus Call operator. seekingalpha.com - 1 week ago

Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024 Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income1 and operating income margin1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous range BAD HOMBURG, Germany , Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The Care Delivery margin extended well into the 2025 margin target band while Care Enablement maintained the significant margin progress realized in the first half year. prnewswire.com - 1 week ago

Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 3 weeks ago

Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024 A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions. prnewswire.com - 3 weeks ago

Here's Why Fresenius (FMS) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago

Fresenius Medical Care: Let's Look At The Upside Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth in 2024, driven by global ESRD demand, at-home treatments, and strategic divestments. Political risks exist, but Fresenius' market-leading position, leverage improvements, and 35% market share in equipment support a "Buy" rating with a $34/share PT. seekingalpha.com - 1 month ago

Here's Why Fresenius (FMS) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago

8. Profile Summary

Fresenius Medical Care AG & Co. KGaA FMS

COUNTRY DE

INDUSTRY Medical - Care Facilities

MARKET CAP $ 13 B

Dividend Yield 0.00%

Description Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Contact Else-KrOener Strasse 1, Bad Homburg, 61352 https://www.freseniusmedicalcare.com

IPO Date Sept. 17, 1996

Employees 113079

Officers Dr. Gail-Suzanne Brown Senior Vice President of Research & Development Dr. Franklin W. Maddux F.A.C.P. Global Chief Medical Officer & Member of Management Board Mr. Jorg Haring Global Head of Legal, Compliance & Human Resources and Labor Director Mr. Martin Fischer Chief Financial Officer & Member of the Management Board Mr. Glenn Slater Senior Vice President of Manufacturing and Supply Chain Operations Mr. Joachim Weith Senior Vice President of Corporate Communications & Governmental Affairs Ms. Helen Giza Chair of Management Board & Chief Executive Officer Dr. Katarzyna Mazur-Hofsab Ph.D. Chief Executive Officer of Care Enablement & Member of Management Board Dr. Dominik Heger Executive Vice President and Head of Investor Relations, Strategic Development & Communications Mr. Craig Cordola FACHE, M.B.A., M.H.A. Chief Executive Officer of Care Delivery & Member of Management Board

Price Chart FMS

Fresenius Medical Care AG & Co. KGaA FMS

Premium Plan

Unlimited Plan